董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kush M. Parmar | 男 | Director | 40 | 未披露 | 未持股 | 2021-06-30 |
| Timothy M. Shannon | 男 | Director | 62 | 未披露 | 未持股 | 2021-06-30 |
| Helen M. Boudreau | 女 | Director | 55 | 9.84万美元 | 未持股 | 2021-06-30 |
| Rob Hopfner | 男 | Director | 48 | 未披露 | 未持股 | 2021-06-30 |
| Lucian Iancovici | 男 | Director | 39 | 未披露 | 未持股 | 2021-06-30 |
| Timothy M. Shannon | -- | Director | 62 | 未披露 | 未持股 | 2021-06-30 |
| Martin W. Mackay | 男 | Chief Executive Officer and Chairman | 65 | 未披露 | 未持股 | 2021-06-30 |
| Martin Mackay | 男 | Chief Executive Officer and Chairman | 65 | 83.81万美元 | 未持股 | 2021-06-30 |
| Ronald M. Hunt | 男 | Director | 56 | 未披露 | 未持股 | 2021-06-30 |
| Paula Soteropoulos | 女 | Director | 53 | 9.13万美元 | 未持股 | 2021-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Martin W. Mackay | 男 | Chief Executive Officer and Chairman | 65 | 未披露 | 未持股 | 2021-06-30 |
| Stephen Uden | -- | President, Chief Operating Officer and Chief Scientific Officer | 63 | 83.81万美元 | 未持股 | 2021-06-30 |
| Jeffrey M. Fryer | 男 | Chief Financial Officer and Treasurer | 52 | 83.81万美元 | 未持股 | 2021-06-30 |
| Steven Ryder | 男 | Chief Medical Officer | 70 | 未披露 | 未持股 | 2021-06-30 |
| Martin Mackay | 男 | Chief Executive Officer and Chairman | 65 | 83.81万美元 | 未持股 | 2021-06-30 |
董事简历
中英对照 | 中文 | 英文- Kush M. Parmar
-
Kush M. Parmar ，从2013年7月起担任Vor Biopharma Inc.董事会成员。他目前担任5AM Ventures（风险资本公司）的一般合伙人，从2010年6月起在5AM Ventures工作。此前，他是Harvard 医学院一家健康医师科学家研究所的院士，在Massachusetts General & Brigham和omen’s Hospitals 完成了临床见习；为肿瘤初创企业提供咨询服务。他还在数个私有企业董事会任职。他还是 Society of Kauffman Fellows的一位院士。持有Princeton 大学学士学位，Harvard 大学博士学位和Harvard 医学院医学博士学位。
Kush M. Parmar has served as our co-chief executive officer and as a member of our board of directors since our inception in August 2020. Dr. Parmar is also Managing Partner at 5AM and joined in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. Dr. Parmar serves or has served as a director on the boards of Akouos, Inc. Nasdaq: AKUS, Arvinas, Inc. (Nasdaq: ARVN), Audentes Therapeutics, Inc. (which was acquired by Astellas Pharma Inc.), Entrada Therapeutics, Inc., Homology Medicines, Inc. (Nasdaq: FIXX), Rallybio Holdings, LLC, scPharmaceuticals, Inc (Nasdaq: SCPH), Vor Biopharma Inc. (Nasdaq: VOR), and Ensoma Inc. He previously served as Acting VP of Strategy and Corporate Development at Novira Therapeutics, Inc. (which was acquired by Johnson & Johnson) and served as board observer for Envoy Therapeutics Inc. (which was acquired by Takeda Pharmaceutical Company Limited), Achaogen, Inc. (Nasdaq: AKAO) and Pulmatrix, Inc. (Nasdaq: PULM). Dr. Parmar serves on the advisory boards of Harvard Medical School, Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School. - Kush M. Parmar ，从2013年7月起担任Vor Biopharma Inc.董事会成员。他目前担任5AM Ventures（风险资本公司）的一般合伙人，从2010年6月起在5AM Ventures工作。此前，他是Harvard 医学院一家健康医师科学家研究所的院士，在Massachusetts General & Brigham和omen’s Hospitals 完成了临床见习；为肿瘤初创企业提供咨询服务。他还在数个私有企业董事会任职。他还是 Society of Kauffman Fellows的一位院士。持有Princeton 大学学士学位，Harvard 大学博士学位和Harvard 医学院医学博士学位。
- Kush M. Parmar has served as our co-chief executive officer and as a member of our board of directors since our inception in August 2020. Dr. Parmar is also Managing Partner at 5AM and joined in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. Dr. Parmar serves or has served as a director on the boards of Akouos, Inc. Nasdaq: AKUS, Arvinas, Inc. (Nasdaq: ARVN), Audentes Therapeutics, Inc. (which was acquired by Astellas Pharma Inc.), Entrada Therapeutics, Inc., Homology Medicines, Inc. (Nasdaq: FIXX), Rallybio Holdings, LLC, scPharmaceuticals, Inc (Nasdaq: SCPH), Vor Biopharma Inc. (Nasdaq: VOR), and Ensoma Inc. He previously served as Acting VP of Strategy and Corporate Development at Novira Therapeutics, Inc. (which was acquired by Johnson & Johnson) and served as board observer for Envoy Therapeutics Inc. (which was acquired by Takeda Pharmaceutical Company Limited), Achaogen, Inc. (Nasdaq: AKAO) and Pulmatrix, Inc. (Nasdaq: PULM). Dr. Parmar serves on the advisory boards of Harvard Medical School, Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.
- Timothy M. Shannon
-
Timothy M. Shannon自2018年4月起担任Rallybio Corporation的董事。Shannon自2015年12月起担任NextCure, Inc.的董事。Shannon博士自2009年11月起担任Canaan Partners的普通合伙人。Shannon博士自2013年7月起担任Arvinas, Inc.（上市生物制药公司，专注于降解致病蛋白质的疗法）的董事会主席。2010年11月至2013年9月，他担任Aldea Pharmaceuticals（专注于治疗有毒醛相关疾病的生物制药公司）的总裁和首席执行官。Shannon博士从2007年到2009年担任CuraGen Corporation的首席执行官，从2004年到2007年担任CuraGen的首席医疗官。从1992年到2002年，Shannon博士担任Bayer Healthcare的各种高级研发职务，包括全球临床开发高级副总裁。2009年10月至2014年12月，担任Celldex Therapeutics, Inc.的董事会成员；2007年9月，担任CuraGen Corporation的董事会成员，直到2009年10月被Celldex收购。他获得了Amherst College的化学学士学位和the University of Connecticut的医学博士学位。
Timothy M. Shannon has served as a member of NextCure, Inc. of directors since December 2015. Dr. Shannon has served as a General Partner at Canaan Partners since November 2009. Dr. Shannon has also served as the chairman of the board of directors at Arvinas, Inc., a publicly traded biopharmaceutical company focused on therapies to degrade disease-causing proteins, since July 2013. Dr. Shannon was the President and Chief Executive Officer of Aldea Pharmaceuticals, a biopharmaceutical company focused on the treatment of toxic aldehyde-related diseases, from November 2010 to September 2013. Dr. Shannon also served as Chief Executive Officer of CuraGen Corporation from 2007 to 2009 and as CuraGen's Chief Medical Officer from 2004 to 2007. From 1992 to 2002 Dr. Shannon served in various senior research and development roles at Bayer Healthcare, including Senior Vice President of Worldwide Clinical Development. Dr. Shannon previously served as a member of the boards of directors of publicly traded CytomX Therapeutics, Inc. from July 2012 to March 2017 Celldex Therapeutics, Inc. from October 2009 to December 2014 and CuraGen Corporation from September 2007 until its acquisition by Celldex in October 2009. Dr. Shannon received a B.A. in chemistry from Amherst College and an M.D. from the University of Connecticut. - Timothy M. Shannon自2018年4月起担任Rallybio Corporation的董事。Shannon自2015年12月起担任NextCure, Inc.的董事。Shannon博士自2009年11月起担任Canaan Partners的普通合伙人。Shannon博士自2013年7月起担任Arvinas, Inc.（上市生物制药公司，专注于降解致病蛋白质的疗法）的董事会主席。2010年11月至2013年9月，他担任Aldea Pharmaceuticals（专注于治疗有毒醛相关疾病的生物制药公司）的总裁和首席执行官。Shannon博士从2007年到2009年担任CuraGen Corporation的首席执行官，从2004年到2007年担任CuraGen的首席医疗官。从1992年到2002年，Shannon博士担任Bayer Healthcare的各种高级研发职务，包括全球临床开发高级副总裁。2009年10月至2014年12月，担任Celldex Therapeutics, Inc.的董事会成员；2007年9月，担任CuraGen Corporation的董事会成员，直到2009年10月被Celldex收购。他获得了Amherst College的化学学士学位和the University of Connecticut的医学博士学位。
- Timothy M. Shannon has served as a member of NextCure, Inc. of directors since December 2015. Dr. Shannon has served as a General Partner at Canaan Partners since November 2009. Dr. Shannon has also served as the chairman of the board of directors at Arvinas, Inc., a publicly traded biopharmaceutical company focused on therapies to degrade disease-causing proteins, since July 2013. Dr. Shannon was the President and Chief Executive Officer of Aldea Pharmaceuticals, a biopharmaceutical company focused on the treatment of toxic aldehyde-related diseases, from November 2010 to September 2013. Dr. Shannon also served as Chief Executive Officer of CuraGen Corporation from 2007 to 2009 and as CuraGen's Chief Medical Officer from 2004 to 2007. From 1992 to 2002 Dr. Shannon served in various senior research and development roles at Bayer Healthcare, including Senior Vice President of Worldwide Clinical Development. Dr. Shannon previously served as a member of the boards of directors of publicly traded CytomX Therapeutics, Inc. from July 2012 to March 2017 Celldex Therapeutics, Inc. from October 2009 to December 2014 and CuraGen Corporation from September 2007 until its acquisition by Celldex in October 2009. Dr. Shannon received a B.A. in chemistry from Amherst College and an M.D. from the University of Connecticut.
- Helen M. Boudreau
-
Helen M.Boudreau于2020年6月加入我们。Boudreau女士在生物技术、制药、咨询和银行业拥有30年的经验。最近，从2018年6月至2019年6月，她担任非营利生物技术比尔及梅林达·盖茨医学研究所的首席运营官。此前，她曾于2017年7月至2018年6月担任首席财务官，并于2016年2月至2017年7月担任ProteostasisTherapeutics，Inc.董事兼审计委员会主席2014年10月至2017年6月，她担任Forma Therapeutics，Inc.的首席财务官。2008年9月至2014年9月，Boudreau女士在Novartis担任高级财务职位，包括首席财务官Novartis Corporation US和首席财务官Global Oncology。从1999年4月到2008年9月，Boudreau女士在辉瑞公司（Pfizer）担任越来越多的战略与财务方面的职务和责任，包括Vice President金融客户业务部和商业运营部以及辉瑞全球研究与开发Vice President金融公司。Boudreau女士在百事可乐/百胜餐饮集团（PepsiCo/Yum！Brands，麦肯锡公司和美国银行。自2020年6月以来，她一直担任梦百合改进公司Premier，Inc.的董事会成员。她也任职Shattuck Labs公司、Field Trip Health公司、Rallybio公司的董事会。Boudreau女士在马里兰大学（University of Maryland）以优异成绩毕业并获得经济学学士学位，在弗吉尼亚大学（University of Virginia）达顿商学院（Darden Graduate School of Business）获得工商管理硕士学位。
Helen M. Boudreau,Previously Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, a nonprofit medical research organization, from 2018 to 2019,Previously served as the Chief Financial Officer at each of Proteostasis Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, from 2017 to 2018, and FORMA Therapeutics, Inc., a privately held biotechnology company, from 2014 to 2017,Prior experience includes executive positions with Novartis Corporation and Pfizer, Inc. and leadership roles with Pepsico/Yum! Brands, Inc., McKinsey & Company, Inc. and Bank of America Corporation,Member of the Board of Directors and as Chair of the Audit Committee of Shattuck Labs, Inc., a NASDAQ-listed company, since July 2020,Member of the Board of Directors and as Chair of the Audit Committee of Rallybio Corporation, a NASDAQ-listed biotech company, since September 2020,Previously served on the Board of Directors and as Chair of the Audit Committee of Cara Therapeutics, a NASDAQ-listed company, from 2023 until its sale in 2025,Previously served on the Board of Directors and as Chair of the Audit Committee and member of the Compensation Committee of Reunion Neuroscience (formerly Field Trip Health Ltd), a company formerly listed on the Toronto Stock Exchange and NASDAQ, from 2020 to 2023,Previously served on the Board of Directors and as Chair of the Audit Committee of Evaxion Biotech, a NASDAQ-listed company, from 2020 to 2021,Previously served on the Board of Directors and as Chair of the Audit Committee and member of the Compensation Committee for Proteostasis Therapeutics, Inc., a NASDAQ-listed company, from 2016 to 2017,NACD Directorship Certified by the National Association of Corporate Directors,Obtained a bachelor's degree from the University of Maryland and a Master of Business Administration from the University of Virginia Darden Graduate School of Business,CERT Certificate in Cyber-Risk Oversight from the Carnegie Mellon University Software Engineering Institute and NACD. - Helen M.Boudreau于2020年6月加入我们。Boudreau女士在生物技术、制药、咨询和银行业拥有30年的经验。最近，从2018年6月至2019年6月，她担任非营利生物技术比尔及梅林达·盖茨医学研究所的首席运营官。此前，她曾于2017年7月至2018年6月担任首席财务官，并于2016年2月至2017年7月担任ProteostasisTherapeutics，Inc.董事兼审计委员会主席2014年10月至2017年6月，她担任Forma Therapeutics，Inc.的首席财务官。2008年9月至2014年9月，Boudreau女士在Novartis担任高级财务职位，包括首席财务官Novartis Corporation US和首席财务官Global Oncology。从1999年4月到2008年9月，Boudreau女士在辉瑞公司（Pfizer）担任越来越多的战略与财务方面的职务和责任，包括Vice President金融客户业务部和商业运营部以及辉瑞全球研究与开发Vice President金融公司。Boudreau女士在百事可乐/百胜餐饮集团（PepsiCo/Yum！Brands，麦肯锡公司和美国银行。自2020年6月以来，她一直担任梦百合改进公司Premier，Inc.的董事会成员。她也任职Shattuck Labs公司、Field Trip Health公司、Rallybio公司的董事会。Boudreau女士在马里兰大学（University of Maryland）以优异成绩毕业并获得经济学学士学位，在弗吉尼亚大学（University of Virginia）达顿商学院（Darden Graduate School of Business）获得工商管理硕士学位。
- Helen M. Boudreau,Previously Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, a nonprofit medical research organization, from 2018 to 2019,Previously served as the Chief Financial Officer at each of Proteostasis Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, from 2017 to 2018, and FORMA Therapeutics, Inc., a privately held biotechnology company, from 2014 to 2017,Prior experience includes executive positions with Novartis Corporation and Pfizer, Inc. and leadership roles with Pepsico/Yum! Brands, Inc., McKinsey & Company, Inc. and Bank of America Corporation,Member of the Board of Directors and as Chair of the Audit Committee of Shattuck Labs, Inc., a NASDAQ-listed company, since July 2020,Member of the Board of Directors and as Chair of the Audit Committee of Rallybio Corporation, a NASDAQ-listed biotech company, since September 2020,Previously served on the Board of Directors and as Chair of the Audit Committee of Cara Therapeutics, a NASDAQ-listed company, from 2023 until its sale in 2025,Previously served on the Board of Directors and as Chair of the Audit Committee and member of the Compensation Committee of Reunion Neuroscience (formerly Field Trip Health Ltd), a company formerly listed on the Toronto Stock Exchange and NASDAQ, from 2020 to 2023,Previously served on the Board of Directors and as Chair of the Audit Committee of Evaxion Biotech, a NASDAQ-listed company, from 2020 to 2021,Previously served on the Board of Directors and as Chair of the Audit Committee and member of the Compensation Committee for Proteostasis Therapeutics, Inc., a NASDAQ-listed company, from 2016 to 2017,NACD Directorship Certified by the National Association of Corporate Directors,Obtained a bachelor's degree from the University of Maryland and a Master of Business Administration from the University of Virginia Darden Graduate School of Business,CERT Certificate in Cyber-Risk Oversight from the Carnegie Mellon University Software Engineering Institute and NACD.
- Rob Hopfner
-
Rob Hopfner自2020年3月起担任Rallybio Corporation的董事。自2017年10月起，他担任Pivotal bioVenture Partners LLC（一家风险投资公司）的管理合伙人。从2007年6月到2009年10月，他担任Bay City Capital LLC（风险投资公司）的负责人；从2009年10月到2017年9月，他担任董事总经理和合伙人。他目前担任Vaxcyte, Inc.和Inozyme Pharma, Inc.的董事会成员，以及一些私人生命科学公司的董事会成员。他持有萨斯喀彻温大学（University of Saskatchewan）的药学学士学位和药理学博士学位，以及芝加哥大学（University of Chicago）的工商管理硕士学位。
Rob Hopfner has served as a member of board of directors since inception in April 2020. Dr. Hopfner is a Managing Partner at TPG Growth, a private equity firm, and has been with TPG since 2007. Prior to TPG, Dr. Hopfner was a Principal at Warburg Pinc, a private equity firm, from 2003 to 2007. Dr. Hopfner received his Ph.D. in economics from the University of California, Berkeley. - Rob Hopfner自2020年3月起担任Rallybio Corporation的董事。自2017年10月起，他担任Pivotal bioVenture Partners LLC（一家风险投资公司）的管理合伙人。从2007年6月到2009年10月，他担任Bay City Capital LLC（风险投资公司）的负责人；从2009年10月到2017年9月，他担任董事总经理和合伙人。他目前担任Vaxcyte, Inc.和Inozyme Pharma, Inc.的董事会成员，以及一些私人生命科学公司的董事会成员。他持有萨斯喀彻温大学（University of Saskatchewan）的药学学士学位和药理学博士学位，以及芝加哥大学（University of Chicago）的工商管理硕士学位。
- Rob Hopfner has served as a member of board of directors since inception in April 2020. Dr. Hopfner is a Managing Partner at TPG Growth, a private equity firm, and has been with TPG since 2007. Prior to TPG, Dr. Hopfner was a Principal at Warburg Pinc, a private equity firm, from 2003 to 2007. Dr. Hopfner received his Ph.D. in economics from the University of California, Berkeley.
- Lucian Iancovici
-
Lucian Iancovici自2020年5月起担任我们的董事会成员。Iancovici博士目前是TPG Growth的董事总经理，自2018年1月起在该公司工作。从2012年9月到2017年10月，Iancovici博士担任高通生命基金（Qualcomm Life Fund）的负责人，该基金是一家专注于投资数字健康技术的风险基金。从2015年1月到2017年10月，Iancovici博士是DRX Capital的普通合伙人，DRX Capital是一家由诺华和高通发起的合资投资公司。从2011年到2012年，Iancovici博士是麦肯锡公司的助理。Lucian是一名董事会认证的内科医生，在加入麦肯锡公司之前曾在纽约哥伦比亚大学医疗中心接受培训。Iancovici博士在塔夫茨大学获得了经济学学士学位和硕士学位。
Lucian Iancovici,is currently a Managing Director with TPG, a private equity investment firm, where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici currently serves on the public company board of directors of Rallybio Corp and Sionna Therapeutics, and on the boards of the following private companies: Sling Therapeutics, Ellodi Pharmaceuticals, Anovo, and K2 Medical Research. Dr. Iancovici is a board-certified internal medicine doctor, who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received a B.A. in economics and an M.D., both from Tufts University. - Lucian Iancovici自2020年5月起担任我们的董事会成员。Iancovici博士目前是TPG Growth的董事总经理，自2018年1月起在该公司工作。从2012年9月到2017年10月，Iancovici博士担任高通生命基金（Qualcomm Life Fund）的负责人，该基金是一家专注于投资数字健康技术的风险基金。从2015年1月到2017年10月，Iancovici博士是DRX Capital的普通合伙人，DRX Capital是一家由诺华和高通发起的合资投资公司。从2011年到2012年，Iancovici博士是麦肯锡公司的助理。Lucian是一名董事会认证的内科医生，在加入麦肯锡公司之前曾在纽约哥伦比亚大学医疗中心接受培训。Iancovici博士在塔夫茨大学获得了经济学学士学位和硕士学位。
- Lucian Iancovici,is currently a Managing Director with TPG, a private equity investment firm, where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici currently serves on the public company board of directors of Rallybio Corp and Sionna Therapeutics, and on the boards of the following private companies: Sling Therapeutics, Ellodi Pharmaceuticals, Anovo, and K2 Medical Research. Dr. Iancovici is a board-certified internal medicine doctor, who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received a B.A. in economics and an M.D., both from Tufts University.
- Timothy M. Shannon
-
暂无中文简介
Timothy M. Shannon has served as a member of our board of directors since April 2018. Dr. Shannon has been both a Non-Managing Member of Canaan Partners IX LLC, a Managing Member of Canaan Partners X LLC, a Managing Member of Canaan Partners XI LLC, and a Managing Member of Canaan Partners XII LLC, all entities affiliated with Canaan Partners, a venture capital firm, since November 2009. While at Canaan, Dr. Shannon served in a number of executive roles at biotechnology companies, including as President and Chief Executive Officer of Aldea Pharmaceuticals, Inc. and of Arvinas, Inc. Prior to Canaan, Dr . Shannon served as Executive Vice President of R&D and Chief Medical Officer of Curagen Corporation and Senior Vice President of Global Medical Development, Bayer Healthcare LLC. Dr. Shannon currently serves as chairman of the board of directors of Arvinas, Inc. and of Ideaya Biosciences, Inc., as well as several privately held companies. Dr. Shannon previously served as a board member of NextCure Inc., and CytomX Therapeutics, Inc. Dr. Shannon earned a B.A. in chemistry from Amherst College and an M.D. from the University of Connecticut. -
暂无中文简介
- Timothy M. Shannon has served as a member of our board of directors since April 2018. Dr. Shannon has been both a Non-Managing Member of Canaan Partners IX LLC, a Managing Member of Canaan Partners X LLC, a Managing Member of Canaan Partners XI LLC, and a Managing Member of Canaan Partners XII LLC, all entities affiliated with Canaan Partners, a venture capital firm, since November 2009. While at Canaan, Dr. Shannon served in a number of executive roles at biotechnology companies, including as President and Chief Executive Officer of Aldea Pharmaceuticals, Inc. and of Arvinas, Inc. Prior to Canaan, Dr . Shannon served as Executive Vice President of R&D and Chief Medical Officer of Curagen Corporation and Senior Vice President of Global Medical Development, Bayer Healthcare LLC. Dr. Shannon currently serves as chairman of the board of directors of Arvinas, Inc. and of Ideaya Biosciences, Inc., as well as several privately held companies. Dr. Shannon previously served as a board member of NextCure Inc., and CytomX Therapeutics, Inc. Dr. Shannon earned a B.A. in chemistry from Amherst College and an M.D. from the University of Connecticut.
- Martin W. Mackay
-
暂无中文简介
Martin W. Mackay is a co-founder of, and has been Chief Executive Officer and Chairman of the board of directors of Rallybio since January 2018. From March 2013 to December 2017 Dr. Mackay served as the Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc., or Alexion, and, from July 2010 to January 2013 Dr. Mackay served as the President of Research & Development at AstraZeneca PLC. Prior to AstraZeneca, Dr. Mackay worked at Pfizer, Inc., or Pfizer, for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr. Mackay currently serves on the board of directors of 5:01 Acquisition Corp, Charles River Laboratories International, Inc., and Novo Nordisk A/S. Dr. Mackay earned a BSc First Class in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University of Edinburgh. -
暂无中文简介
- Martin W. Mackay is a co-founder of, and has been Chief Executive Officer and Chairman of the board of directors of Rallybio since January 2018. From March 2013 to December 2017 Dr. Mackay served as the Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc., or Alexion, and, from July 2010 to January 2013 Dr. Mackay served as the President of Research & Development at AstraZeneca PLC. Prior to AstraZeneca, Dr. Mackay worked at Pfizer, Inc., or Pfizer, for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr. Mackay currently serves on the board of directors of 5:01 Acquisition Corp, Charles River Laboratories International, Inc., and Novo Nordisk A/S. Dr. Mackay earned a BSc First Class in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University of Edinburgh.
- Martin Mackay
-
Martin Mackay博士。Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
Martin Mackay,is co-founder, former Chief Executive Officer (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and, from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay has served as a director of Novo Nordisk since March 2018 and SpringWorks Therapeutics since 2024. From October 2020 through April 2022, Dr. Mackay served as a director of 5:01 Acquisition Corp. Dr. Mackay has been a director of the Company since July 2017. - Martin Mackay博士。Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
- Martin Mackay,is co-founder, former Chief Executive Officer (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and, from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay has served as a director of Novo Nordisk since March 2018 and SpringWorks Therapeutics since 2024. From October 2020 through April 2022, Dr. Mackay served as a director of 5:01 Acquisition Corp. Dr. Mackay has been a director of the Company since July 2017.
- Ronald M. Hunt
-
Ronald M. Hunt，他担任董事（2012年7月以来）。他曾一直担任New Leaf Venture Partners公司（风险资本公司）的董事总经理（2005年以来），专注于投资生物制药公司。此前，他曾任职the Sprout Group（风险资本公司），担任cCoopers & Lybrand Consulting公司和The Health Care Group的咨询公司的顾问。进入咨询领域之前，他曾担任Johnson & Johnson公司和SmithKline Beecham Pharmaceuticals公司的多种销售和市场营销职位。他目前任职于Durata Therapeutics公司（一个制药公司）的董事会。他持有Cornell大学的工商管理和市场营销学士学位，以及Pennsylvania大学沃顿商学院的工商管理硕士学位。
Ronald M. Hunt has served as a member of board of directors since March 2019. Since 2005 Mr. Hunt has served as a Managing Director and Member of New Leaf Venture Partners, L.L.C., a venture capital firm. Previously, Mr. Hunt served at the Sprout Group, a venture capital firm and was a consultant with consulting firms Coopers & Lybrand Consulting and The Health Care Group, Inc. Mr. Hunt worked earlier in his career in various sales and marketing positions at Johnson & Johnson and SmithKline Beecham Pharmaceuticals PLC. Mr. Hunt currently serves as a board member of Harpoon Therapeutics, Inc. and Iterum Therapeutics, Ltd., a clinical-stage therapeutics company, and on the boards of a number of private pharmaceutical and healthcare companies. Mr. Hunt previously served on the board of directors of Neuronetics, Inc. Mr. Hunt earned a B.S. from Cornell University and an M.B.A. from the Wharton School of the University of Pennsylvania. - Ronald M. Hunt，他担任董事（2012年7月以来）。他曾一直担任New Leaf Venture Partners公司（风险资本公司）的董事总经理（2005年以来），专注于投资生物制药公司。此前，他曾任职the Sprout Group（风险资本公司），担任cCoopers & Lybrand Consulting公司和The Health Care Group的咨询公司的顾问。进入咨询领域之前，他曾担任Johnson & Johnson公司和SmithKline Beecham Pharmaceuticals公司的多种销售和市场营销职位。他目前任职于Durata Therapeutics公司（一个制药公司）的董事会。他持有Cornell大学的工商管理和市场营销学士学位，以及Pennsylvania大学沃顿商学院的工商管理硕士学位。
- Ronald M. Hunt has served as a member of board of directors since March 2019. Since 2005 Mr. Hunt has served as a Managing Director and Member of New Leaf Venture Partners, L.L.C., a venture capital firm. Previously, Mr. Hunt served at the Sprout Group, a venture capital firm and was a consultant with consulting firms Coopers & Lybrand Consulting and The Health Care Group, Inc. Mr. Hunt worked earlier in his career in various sales and marketing positions at Johnson & Johnson and SmithKline Beecham Pharmaceuticals PLC. Mr. Hunt currently serves as a board member of Harpoon Therapeutics, Inc. and Iterum Therapeutics, Ltd., a clinical-stage therapeutics company, and on the boards of a number of private pharmaceutical and healthcare companies. Mr. Hunt previously served on the board of directors of Neuronetics, Inc. Mr. Hunt earned a B.S. from Cornell University and an M.B.A. from the Wharton School of the University of Pennsylvania.
- Paula Soteropoulos
-
Paula Soteropoulos，自2013年7月开始，一直担任监事会的成员。从2013年7月起，Soteropoulos女士还一直担任Moderna Therapeutics, Inc.心脏疗法的商业和战略联盟部门的高级副总裁兼总经理。在这以前，从1992到2013年，Soteropoulos女士曾在Genzyme公司就职，一家生物技术公司，最近担任的职位是罕见心血管疾病部门的副总裁和总经理。Soteropoulos女士持有Tufts大学化学工程学位学士学位和生物化学工程硕士学位，以及Virginia大学达顿商学院的工商管理研究生院的行政管理证书。
Paula Soteropoulos, has served as a member of Board since July 2013. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. She currently serves as the Executive Chairman of Ensoma, a private venture-backed company. Since November 2020 she has served on the Board of Directors of Rallybio, LLC. Since March 2020 she also has served as a Strategic Advisor to 5AM Ventures. From January 2015 through September 2019 she served as President and Chief Executive Officer of Akcea Therapeutics NASDAQ: AKCA. From July 2013 to December 2014 she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013 most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a Bachelor of Science degree in chemical engineering and a Master of Science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University. - Paula Soteropoulos，自2013年7月开始，一直担任监事会的成员。从2013年7月起，Soteropoulos女士还一直担任Moderna Therapeutics, Inc.心脏疗法的商业和战略联盟部门的高级副总裁兼总经理。在这以前，从1992到2013年，Soteropoulos女士曾在Genzyme公司就职，一家生物技术公司，最近担任的职位是罕见心血管疾病部门的副总裁和总经理。Soteropoulos女士持有Tufts大学化学工程学位学士学位和生物化学工程硕士学位，以及Virginia大学达顿商学院的工商管理研究生院的行政管理证书。
- Paula Soteropoulos, has served as a member of Board since July 2013. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. She currently serves as the Executive Chairman of Ensoma, a private venture-backed company. Since November 2020 she has served on the Board of Directors of Rallybio, LLC. Since March 2020 she also has served as a Strategic Advisor to 5AM Ventures. From January 2015 through September 2019 she served as President and Chief Executive Officer of Akcea Therapeutics NASDAQ: AKCA. From July 2013 to December 2014 she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013 most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a Bachelor of Science degree in chemical engineering and a Master of Science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.
高管简历
中英对照 | 中文 | 英文- Martin W. Mackay
- 暂无中文简介
Martin W. Mackay is a co-founder of, and has been Chief Executive Officer and Chairman of the board of directors of Rallybio since January 2018. From March 2013 to December 2017 Dr. Mackay served as the Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc., or Alexion, and, from July 2010 to January 2013 Dr. Mackay served as the President of Research & Development at AstraZeneca PLC. Prior to AstraZeneca, Dr. Mackay worked at Pfizer, Inc., or Pfizer, for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr. Mackay currently serves on the board of directors of 5:01 Acquisition Corp, Charles River Laboratories International, Inc., and Novo Nordisk A/S. Dr. Mackay earned a BSc First Class in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University of Edinburgh. - 暂无中文简介
- Martin W. Mackay is a co-founder of, and has been Chief Executive Officer and Chairman of the board of directors of Rallybio since January 2018. From March 2013 to December 2017 Dr. Mackay served as the Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc., or Alexion, and, from July 2010 to January 2013 Dr. Mackay served as the President of Research & Development at AstraZeneca PLC. Prior to AstraZeneca, Dr. Mackay worked at Pfizer, Inc., or Pfizer, for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr. Mackay currently serves on the board of directors of 5:01 Acquisition Corp, Charles River Laboratories International, Inc., and Novo Nordisk A/S. Dr. Mackay earned a BSc First Class in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University of Edinburgh.
- Stephen Uden
Stephen Uden是RallyBio的联合创始人，自2018年1月起担任总裁、首席运营官和首席科学官。此前，2014年6月至2017年10月，Uden博士担任Alexion研究高级副总裁。在Alexion之前，Uden博士在Novartis Japan、Wyeth（日本）、Neurogen和Pfizer的研究机构担任过各种领导职务。Uden博士在伦敦大学获得生物化学学士学位和医学M.B.，B.S.学位。
Stephen Uden is a co-founder of, and has been President, Chief Operating Officer and Chief Scientific Officer of Rallybio since January 2018. Previously, Dr. Uden served as Senior Vice President, Research at Alexion from June 2014 to October 2017. Prior to Alexion, Dr. Uden served in various leadership roles in the research organizations of Novartis Japan, Wyeth (Japan), Neurogen and Pfizer. Dr. Uden earned a BSc in biochemistry and an M.B., B.S. in medicine from the University of London.- Stephen Uden是RallyBio的联合创始人，自2018年1月起担任总裁、首席运营官和首席科学官。此前，2014年6月至2017年10月，Uden博士担任Alexion研究高级副总裁。在Alexion之前，Uden博士在Novartis Japan、Wyeth（日本）、Neurogen和Pfizer的研究机构担任过各种领导职务。Uden博士在伦敦大学获得生物化学学士学位和医学M.B.，B.S.学位。
- Stephen Uden is a co-founder of, and has been President, Chief Operating Officer and Chief Scientific Officer of Rallybio since January 2018. Previously, Dr. Uden served as Senior Vice President, Research at Alexion from June 2014 to October 2017. Prior to Alexion, Dr. Uden served in various leadership roles in the research organizations of Novartis Japan, Wyeth (Japan), Neurogen and Pfizer. Dr. Uden earned a BSc in biochemistry and an M.B., B.S. in medicine from the University of London.
- Jeffrey M. Fryer
Jeffrey M.Fryer是RallyBio的联合创始人，自2018年1月起担任首席财务官兼财务主管。此前，从2008年4月到2017年4月，Fryer先生担任Alexion的副总裁兼首席税务官。在Alexion之前，Fryer先生在Chemtura Corporation和Lydall，Inc.领导公司税务职能，并在PwC担任高级税务经理超过10年。他在哈特福德大学（University of Hartford）获得税务硕士学位，在布莱恩特大学（Bryant University）获得工商管理学士学位，专注于会计。Fryer先生是布莱恩特大学商学院院长顾问委员会的成员。
Jeffrey M. Fryer is a co-founder of, and has been Chief Financial Officer and Treasurer of Rallybio since January 2018. Previously, Mr. Fryer served as Vice-President and Chief Tax Officer of Alexion from April 2008 to April 2017. Prior to Alexion, Mr. Fryer lead the corporate tax functions at Chemtura Corporation and Lydall, Inc., and served for over ten years with PwC as a senior tax manager. He earned an M.S. in taxation from the University of Hartford and a B.S. in business administration with a concentration in accounting from Bryant University. Mr. Fryer is a member of the Dean’s Advisory Council for the Bryant University School of Business.- Jeffrey M.Fryer是RallyBio的联合创始人，自2018年1月起担任首席财务官兼财务主管。此前，从2008年4月到2017年4月，Fryer先生担任Alexion的副总裁兼首席税务官。在Alexion之前，Fryer先生在Chemtura Corporation和Lydall，Inc.领导公司税务职能，并在PwC担任高级税务经理超过10年。他在哈特福德大学（University of Hartford）获得税务硕士学位，在布莱恩特大学（Bryant University）获得工商管理学士学位，专注于会计。Fryer先生是布莱恩特大学商学院院长顾问委员会的成员。
- Jeffrey M. Fryer is a co-founder of, and has been Chief Financial Officer and Treasurer of Rallybio since January 2018. Previously, Mr. Fryer served as Vice-President and Chief Tax Officer of Alexion from April 2008 to April 2017. Prior to Alexion, Mr. Fryer lead the corporate tax functions at Chemtura Corporation and Lydall, Inc., and served for over ten years with PwC as a senior tax manager. He earned an M.S. in taxation from the University of Hartford and a B.S. in business administration with a concentration in accounting from Bryant University. Mr. Fryer is a member of the Dean’s Advisory Council for the Bryant University School of Business.
- Steven Ryder
Steven Ryder自2019年1月起担任RallyBio的首席医疗官。此前，Ryder博士从2013年7月到2018年12月担任Alexion的首席发展官。从2008年4月到2013年4月，Ryder博士担任Astellas Inc.或Astellas的Astellas Pharma全球开发总裁。在加入Astellas之前，Ryder博士在Pfizer工作了21年，在那里他担任越来越多的职务，包括全球临床开发主管。赖德博士在西奈山的伊坎医学院获得了医学博士学位。
Steven Ryder,has served on board of directors since January 2024. Dr. Ryder has served as the Chief Medical Officer of Rallybio Corporation (Nasdaq: RLYB) since January 2019. Previously, Dr. Ryder was the Chief Development Officer at Alexion Pharmaceuticals, Inc. (Nasdaq: Formerly ALXN, acquired by AstraZeneca PLC) from July 2013 to December 2018 and was the founding President of Astellas Pharma Global Development, Inc. from April 2008 to April 2013. Dr. Ryder also worked at Pfizer Inc. (Nasdaq: PFE) for 21 years where he held positions of increasing responsibility, including head of worldwide clinical development. He has also held board positions at Reata Pharmaceuticals, Inc. (Nasdaq: Formerly RETA, acquired by Biogen Inc. (Nasdaq: BIIB)) from July 2022 to September 2023 and Levo Therapeutics, Inc. Dr. Ryder earned his Doctor of Medicine from the Icahn School of Medicine at Mount Sinai.- Steven Ryder自2019年1月起担任RallyBio的首席医疗官。此前，Ryder博士从2013年7月到2018年12月担任Alexion的首席发展官。从2008年4月到2013年4月，Ryder博士担任Astellas Inc.或Astellas的Astellas Pharma全球开发总裁。在加入Astellas之前，Ryder博士在Pfizer工作了21年，在那里他担任越来越多的职务，包括全球临床开发主管。赖德博士在西奈山的伊坎医学院获得了医学博士学位。
- Steven Ryder,has served on board of directors since January 2024. Dr. Ryder has served as the Chief Medical Officer of Rallybio Corporation (Nasdaq: RLYB) since January 2019. Previously, Dr. Ryder was the Chief Development Officer at Alexion Pharmaceuticals, Inc. (Nasdaq: Formerly ALXN, acquired by AstraZeneca PLC) from July 2013 to December 2018 and was the founding President of Astellas Pharma Global Development, Inc. from April 2008 to April 2013. Dr. Ryder also worked at Pfizer Inc. (Nasdaq: PFE) for 21 years where he held positions of increasing responsibility, including head of worldwide clinical development. He has also held board positions at Reata Pharmaceuticals, Inc. (Nasdaq: Formerly RETA, acquired by Biogen Inc. (Nasdaq: BIIB)) from July 2022 to September 2023 and Levo Therapeutics, Inc. Dr. Ryder earned his Doctor of Medicine from the Icahn School of Medicine at Mount Sinai.
- Martin Mackay
Martin Mackay博士。Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
Martin Mackay,is co-founder, former Chief Executive Officer (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and, from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay has served as a director of Novo Nordisk since March 2018 and SpringWorks Therapeutics since 2024. From October 2020 through April 2022, Dr. Mackay served as a director of 5:01 Acquisition Corp. Dr. Mackay has been a director of the Company since July 2017.- Martin Mackay博士。Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
- Martin Mackay,is co-founder, former Chief Executive Officer (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and, from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay has served as a director of Novo Nordisk since March 2018 and SpringWorks Therapeutics since 2024. From October 2020 through April 2022, Dr. Mackay served as a director of 5:01 Acquisition Corp. Dr. Mackay has been a director of the Company since July 2017.